Development

Financial technology startup Nium recently announced a $50 million fundraising round, with plans to go public within the next 18 months. The round was led by a Southeast Asian sovereign wealth fund and supported by venture capital firms BOND, NewView Capital, and Tribe Capital. Despite the significant amount raised, Nium’s valuation now stands at $1.4
0 Comments
Scorpion Capital’s recent investigative report on Lasertec Corp (TYO:6920) has sent shockwaves through the investing world. The report boldly accuses Lasertec of engaging in fraudulent activities to inflate revenue, margins, and earnings. According to Scorpion Capital, Lasertec’s accounting practices represent one of the largest corporate frauds in Japanese history, with a market cap of $23
0 Comments
The Asian stock market experienced a boost on Wednesday. This was mirrored by a stable performance of the dollar amidst concerns about a potential interest rate cut by the Federal Reserve in September. Despite this positive trend, apprehensions about a slowdown in the U.S. economy limited risk appetite among investors. In Asia, the focus was
0 Comments
Bath & Body Works recently experienced a significant drop in their stock price, with a 14% decline marking their worst day since 2021. This decline followed the release of first-quarter earnings and revenue that beat estimates, however, the company offered a disappointing outlook for the second quarter. With earnings expected to be lower than anticipated,
0 Comments
Cisco’s ThousandEyes internet monitoring unit recently introduced cutting-edge artificial intelligence-powered capabilities designed to significantly enhance the prediction and diagnosis of internet outages and disruptions. The latest AI technology, known as Digital Experience Assurance (DXA), equips customers utilizing Cisco’s networking technology with the ability to proactively address network quality issues automatically. This marks a significant shift
0 Comments
Moderna and Merck recently shared positive three-year data on their experimental vaccine in combination with Keytruda for patients with the most deadly form of skin cancer. The combination of the vaccine and Keytruda showed significant improvements in survival rates and exhibited long-lasting efficacy in a midstage study presented at the American Society of Clinical Oncology
0 Comments